2 not yet recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Urodynamics, EG110A, Patient-reported Outcome - Urinary Bladder, Overactive, Spinal Cord Injury | Phase 1 / Phase 2 | Not yet recruiting | Cyllene Therapeutics | 16 | 2026-04-01 | 2025-11-12 |
| Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder. TRG-200 KIT - Overactive Bladder (OAB) | Phase 2 | Not yet recruiting | Trigone Pharma Ltd. | 60 | 2026-02-15 | 2026-02-06 |
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Lower Urinary Tract Symptoms (2) · Male Urogenital Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Urinary Bladder Diseases (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Urological Manifestations (2) · Central Nervous System Diseases (1) · Nervous System Diseases (1) · Spinal Cord Diseases (1) · Trauma, Nervous System (1) · Wounds and Injuries (1)
Patient Reported Outcome Measures (1) · Urodynamics (1)
Cyllene Therapeutics (1) · Trigone Pharma Ltd. (1)
Israel (1) · United States (1)